ENCell Co., Ltd. (KOSDAQ:456070)

South Korea flag South Korea · Delayed Price · Currency is KRW
5,860.00
-210.00 (-3.46%)
Jul 21, 2026, 3:30 PM KST
Market Cap64.63B -52.5%
Revenue (ttm)4.47B -31.3%
Net Income-16.72B
EPS-1,532.05
Shares Out 11.03M
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume55,860
Open5,960.00
Previous Close6,070.00
Day's Range5,780.00 - 6,100.00
52-Week Range5,780.00 - 20,950.00
Betan/a
Analystsn/a
Price Targetn/a
Earnings Daten/a

About ENCell

ENCell Co., Ltd. develops cell/gene-based biopharmaceutical products in South Korea. The company develops EN00, an allogeneic umbilical cord-derived mesenchymal stem cell treatment for Charcot-Marie-Tooth disease. It also provides contracting development and manufacturing services for biopharmaceutical products. The company was founded in 2018 and is based in Seoul, South Korea. [Read more]

Industry Biotechnology
Sector Healthcare
Founded 2018
Country South Korea
Stock Exchange KOSDAQ
Ticker Symbol 456070
Full Company Profile

Financial Performance

In 2025, ENCell's revenue was 5.26 billion, a decrease of -27.06% compared to the previous year's 7.21 billion. Losses were -16.11 billion, 5.90% more than in 2024.

Financial Statements